Back to today’s briefing

Story perspectives

Evoxac Boosts Salivary Flow for Sjögren’s Syndrome Patients

1/14/2025

32 3

Summary

Story summary

A comprehensive analysis of three clinical trials reveals that Evoxac (cevimeline hydrochloride) dramatically enhances salivary flow and alleviates dry mouth for patients suffering from Sjögren’s syndrome. Particularly beneficial for those with mild to moderate symptoms, this promising treatment calls for additional studies to ensure its effectiveness across various demographics.

1 of 1

Story summary

A comprehensive analysis of three clinical trials reveals that Evoxac (cevimeline hydrochloride) dramatically enhances salivary flow and alleviates dry mouth for patients suffering from Sjögren’s syndrome. Particularly beneficial for those with mild to moderate symptoms, this promising treatment calls for additional studies to ensure its effectiveness across various demographics.